David A. Kircher
University of Utah
16 Papers
9 Citations
David A. Kircher is an academic researcher from University of Utah. The author has contributed to research in topics: Melanoma & Biology. The author has an hindex of 6, co-authored 8 publications. Previous affiliations of David A. Kircher include Huntsman Cancer Institute.
Chat about Author
Papers
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.
Grant M. Fischer,Ali Jalali,David A. Kircher,Won-Chul Lee,Jennifer L. McQuade,Lauren E. Haydu,Aron Y. Joon,Alexandre Reuben,Mariana Petaccia de Macedo,Fernando Carapeto,Chendong Yang,Anuj Srivastava,Chandrashekar R. Ambati,Arun Sreekumar,Courtney W. Hudgens,Barbara Knighton,Wanleng Deng,Sherise D. Ferguson,Hussein Abdul-Hassan Tawbi,Isabella C. Glitza,Jeffrey E. Gershenwald,Y.N. Vashisht Gopal,Patrick Hwu,Jason T. Huse,Jennifer A. Wargo,P. Andrew Futreal,Nagireddy Putluri,Alexander J. Lazar,Ralph J. DeBerardinis,Joseph R. Marszalek,Jianjun Zhang,Sheri L. Holmen,Michael T. Tetzlaff,Michael A. Davies +33 more
TL;DR: RNA sequencing on 88 resected MBMs and 42 patient-matched extracranial metastases identified significant immunosuppression and enrichment of oxidative phosphorylation (OXPHOS) in MBMs.
AKT1 Activation Promotes Development of Melanoma Metastases
Joseph H. Cho,James P. Robinson,Rowan A. Arave,William J. Burnett,David A. Kircher,Guo Chen,Michael A. Davies,Allie H. Grossmann,Matthew W. VanBrocklin,Martin McMahon,Sheri L. Holmen,Sheri L. Holmen +11 more
TL;DR: It is demonstrated that AKT1 activation is sufficient to elicit lung and brain metastases in this context and revealed that activation ofAKT1 is distinct from PTEN silencing in metastatic melanoma progression.
138
Melanoma Brain Metastasis: Mechanisms, Models, and Medicine
TL;DR: An overview of newly discovered mechanisms of melanoma spread to the brain is provided, preclinical models that are being used to further the understanding of this deadly disease are discussed and an update of the current clinical trials for melanoma patients with brain metastases is provided.
60
AKT1E17K activates focal adhesion kinase and promotes melanoma brain metastasis
David A. Kircher,David A. Kircher,Kirby A. Trombetti,Mark R. Silvis,Gennie L. Parkman,Gennie L. Parkman,Grant M. Fischer,Stephanie N. Angel,Christopher M. Stehn,Sean C. Strain,Allie H. Grossmann,Allie H. Grossmann,Allie H. Grossmann,Keith L. Duffy,Kenneth M. Boucher,Kenneth M. Boucher,Martin McMahon,Martin McMahon,Michael A. Davies,Michelle C. Mendoza,Michelle C. Mendoza,Matthew W. VanBrocklin,Matthew W. VanBrocklin,Sheri L. Holmen,Sheri L. Holmen +24 more
TL;DR: It is suggested that AKT1E17K promotes melanoma brain metastasis through activation of FAK and provides a rationale for the therapeutic targeting of AKT and/or FAK to reduce melanoma metastasis.
Melanoma metastases caught in the AKT.
TL;DR: Dysregulated protein kinase B alpha (PKB/AKT1) signaling has been increasingly implicated in melanoma metastasis to distant organs, especially the brain, and activation of AKT1 decreased tumor latency and elicited lung and brain metastases in this context.
9